Wockhardt Submits New Drug Application to U.S. FDA for Zidebactam – Cefepime (WCK 5222) for Treatment of Serious Gram – Negative Infections
Wockhardt Submits New Drug Application to U.S. FDA for Zidebactam – Cefepime (WCK 5222) for Treatment of Serious Gram – Negative Infections
News Paper Extract – Notice to Shareholders regarding special window for re – lodgement of transfer of physical shares Sept 2025
PRESTIGIOUS MEDICAL AND PUBLIC HEALTH JOURNAL “THE LANCET REGIONAL HEALTH” PUBLISHES PIVOTAL PHASE 3 CLINICAL STUDY ON MIQNAF® (NAFITHROMYCIN) – A LANDMARK FOR INDIA’S ANTIBIOTIC INNOVATION
Prestigious Medical and Public Health Journal “THE LANCET Regional Health” Publishes Pivotal Phase 3 Clinical Study on Miqnaf® (Nafithromycin) – A Landmark for India’s Antibiotic Innovation
